NeoGenomics (NEO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter
April 30, 2019 7:05 AM EDTFT. MYERS, FL / ACCESSWIRE / April 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2019.
First Quarter 2019 Highlights:
Consolidated revenue increased 51% to $95.6 million Clinical Services revenue increased 51% to $86.2 million Pharma Services revenue increased 45% to $9.4 million Gross profit increased 73% to $47.1 millionDouglas M. VanOort, the Company's Chairman and CEO, commented, "We are certainly pleased with our very strong... More
